Document is current

Article History

Received: 20 April 2020

Accepted: 19 June 2020

First Online: 2 July 2020

Ethics approval and consent to participate

: This retrospective study was performed in accordance with the Declaration of Helsinki and received a waiver of consent by institutional board approval at the Memorial Sloan Kettering Cancer Center and Cleveland Clinic Taussig Cancer Institute.

: Not applicable.

: Yasser Ged has no relationships to disclose.Ruby Gupta has no relationships to disclose.Cihan Duzgol has no relationships to disclose.Andrea Knezevic has no relationships to disclose.Natalie Shapnik has no relationships to disclose.Ritesh Kotecha has no relationships to disclose.Martin H. Voss reports receiving commercial research grants from Bristol-Myers Squibb and Genentech/Roche. Honoraria from Novartis. Travel/accommodation from Eisai, Novartis, and Takeda. Consultant/advisory board member for- Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis, and Pfizer.Darren R. Feldman reports research support from Novartis and Seattle Genetics.Oguz Akin has no relationships to disclose.Sujata Patil has no relationships to disclose.Robert J. Motzer reports receiving commercial research grants from Pfizer, Eisai, Exelixis, Bristol-Myers Squibb, Genentech/Roche, and Novartis, and is a consultant/advisory board member for Pfizer, Merck, Genentech, Exelixis, Eisai, and Novartis.Brian Rini reports receiving research funding from Pfizer, Merck, GNE/Roche, Peloton, Aveo, Astra-Zeneca, and BMS, and is consultant/advisory board member for BMS, Pfizer, Aveo, GNE/Roche, Compugen, Merck, Corvus, and Exelixis, and holds stocks in PTC Therapeutics.Chung-Han Lee reports receiving commercial research grants from BMS, Eisai, Exelixis, Pfizer, and Calithera, and is a consultant/advisory board member for Amgen, BMS, Exelixis, and Eisai.